09/10/2026
e-Updates
"Continuous Glucose Monitoring and Long-Term Glycemic and Kidney Outcomes"
The study included 25 648 individuals (2771 in the Real-time continuous glucose monitoring (rtCGM) arm and 22 877 in the control arm) who were target trial eligible (mean [SD] age, 61.5 [13.1] years; 13 885 [54.7%] male). The mean (SD) baseline HbA1c level was 9.5% (1.5%). After 36 months of follow-up, the rtCGM arm had an approximately 0.8–percentage point lower HbA1c level than controls (7.83% [95% CI, 7.55%-8.11%] vs 8.58% [95% CI, 8.49%-8.66%], P < .001). There was substantial attrition during follow-up; 1228 (44.3%) in the rtCGM arm were censored due to discontinuation and 4284 (18.7%) in the control group were censored due to CGM initiation. There were no significant differences in urinary albumin-creatinine ratio (UACR) between arms initially; however, by the end of 36 months, rtCGM initiators had a UACR of 125.3 mg/g (95% CI, −196.6 to −54.0 mg/g; P = .001) lower than that of controls. There were no differences in eGFR during follow-up.
In this comparative effectiveness study using a target trial emulation, sustained, longer-term use of rtCGM was associated with durable improvements in glycemic control and later regression of UACR. By addressing glycemic deterioration, rtCGM may extend the time before pharmacologic escalation is required and potentially delay diabetic kidney disease progression.
JAMA Network. 2026
Read more on our blog:
www.everestpharmaceuticals.com.np
